ArticleGene therapy2001
The telomerase reverse transcriptase promoter drives efficacious tumor suicide gene therapy while preventing hepatotoxicity encountered with constitutive promoters.
Article in Gene therapy, 2001. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 40 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
40 citing papers in PubMed, 116 citations in OpenAlex.
- Neomorphic DNA-binding enables tumor-specific therapeutic gene expression in fusion-addicted childhood sarcoma.Molecular cancer · 2022Article
- Review
- Article
- Synergistic Effect of Expressed miR-128 and Puma Protein on Targeted Induction of Tumor Cell Apoptosis.Iranian journal of biotechnology · 2016Article
- Tumor-specific expression of shVEGF and suicide gene as a novel strategy for esophageal cancer therapy.World journal of gastroenterology · 2016Article
- Detecting Tumor Metastases: The Road to Therapy Starts Here.Advances in cancer research · 2016Review
- Targeted expression of suicide gene by tissue-specific promoter and microRNA regulation for cancer gene therapy.PloS one · 2013Article
- Gene therapy using the human telomerase catalytic subunit gene promoter enables targeting of the therapeutic effects of vesicular stomatitis virus matrix protein against human lung adenocarcinoma.Experimental and therapeutic medicine · 2012Article
- Frontiers in Suicide Gene Therapy of Cancer.Journal of genetic syndromes & gene therapy · 2012Article
- Is telomerase a viable target in cancer?Mutation research · 2012Review
- Application of mRNA regulatory regions to improve tumor specificity of transgene expression.Cancer gene therapy · 2011Article
- Identification and functional characterization of glioma-specific promoters and their application in suicide gene therapy.Journal of neuro-oncology · 2011Article
- Targeting telomerase-expressing cancer cells.Journal of cellular and molecular medicine · 2011Review
- Targeted antitumor effect induced by hTERT promoter mediated ODC antisense adenovirus.Molecular biology reports · 2010Article
- Systemic administration of a PEGylated adenovirus vector with a cancer-specific promoter is effective in a mouse model of metastasis.Gene therapy · 2009Article
- Use of the Rad51 promoter for targeted anti-cancer therapy.Proceedings of the National Academy of Sciences of the United States of America · 2008Article
- Therapeutic molecular targeting of 15-lipoxygenase-1 in colon cancer.Molecular therapy : the journal of the American Society of Gene Therapy · 2008Article
- Construction of double suicide genes system controlled by MDR1 promoter with targeted expression in drug-resistant glioma cells.Journal of neuro-oncology · 2008Article
- Replication-deficient rSV40 mediate pancreatic gene transfer and long-term inhibition of tumor growth.Cancer gene therapy · 2007Article
- Visualization of telomerase reverse transcriptase (hTERT) promoter activity using a trimodality fusion reporter construct.Journal of nuclear medicine : official publication, Society of Nuclear Medicine · 2006Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors at 2 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
In human cells, telomerase activity is regulated by transcriptional control of the telomerase reverse transcriptase gene (hTERT) whose product is the catalytic subunit of the enzyme. The hTERT promoter is active in virtually all types of tumors and immortal cells, but is silent in most adult somatic tissues. In this study, we placed the herpes simplex virus thymidine kinase gene under the control of the hTERT promoter with the aim of restricting its expression to tumor cells. In transfection experiments, the hTERT promoter driven thymidine kinase gene (hTERTp/TK) conferred ganciclovir sensitivity to all tumor and immortal cell lines tested, whereas normal somatic cells remained largely unaffected. Human hTERTp/TK-positive cancer cells implanted in nude mice developed into tumors that could be eradicated by ganciclovir treatment. The hTERTp/TK cassette was inserted into an adenovirus vector and its efficacy in reducing tumor growth was compared with that of an adenovirus carrying the thymidine kinase gene under the control of the cytomegalovirus immediate-early promoter (CMVp/TK). In a xenograft model using the human 143B osteosarcoma cell line, a single injection of either virus resulted in equivalent tumor regression and survival upon ganciclovir treatment. In animals injected intratumorally with the CMVp/TK adenovirus, expression of the thymidine kinase gene was detected in tumors, as well as in liver samples. Expression of the suicide gene in combination with ganciclovir resulted in severe liver histopathology and in an elevation of hepatic enzymes. In sharp contrast, when the hTERT promoter controlled the thymidine kinase gene, transgene expression was observed in tumors, but not in liver samples. Normal liver function in these animals was confirmed by serum levels of hepatic enzymes that were indistinguishable from those of control healthy mice. These results indicate that by restricting thymidine kinase expression to tumor cells, the hTERT promoter allows the tumoricidal effect of the suicidal gene to be exerted without detrimental consequences on healthy tissues and vital organs. The tight specificity of expression imparted by the hTERT promoter will assist the development of novel approaches to the treatment of a broad array of cancer types.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.